We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

SEC Filings

Form 424B5
AC IMMUNE SA filed this Form 424B5 on 07/20/2018
Document Outline
Entire Document (921.6 KB)
Subdocument 1 - 424B5 - FORM 424B5
Page 1 - PROSPECTUS
Page 2 - TABLE OF CONTENTS
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - AC Immune SA
Page 8 - Our Strategy
Page 9 - N/A
Page 10 - Recent Developments
Page 11 - Implications of Being a Foreign Private Issuer
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - Risks Related to Our Common Shares and the Rights Offering
Page 16 - Shareholders may not be able to exercise pre-emptive subscription rights.
Page 17 - There is only a limited free float of our common shares; this may have a negative impact on the liqu
Page 18 - We do not expect to pay dividends in the foreseeable future.
Page 19 - U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against us or our
Page 20 - Our status as a Swiss corporation means that our shareholders enjoy certain rights that may limit ou
Page 21 - Shareholders in countries with a currency other than Swiss Francs face additional investment risks f
Page 22 - We may lose our foreign private issuer status, which would then require us to comply with the Exchan
Page 23 - If we fail to maintain an effective system of internal control over financial reporting, we may not
Page 24 - Although we believe that we were not a passive foreign investment company, or PFIC, for U.S. federal
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - The Rights Offering
Page 30 - The Offered Shares
Page 31 - N/A
Page 32 - Swiss Tax considerations
Page 33 - Taxation in respect of Offered Shares
Page 34 - Swiss income taxes
Page 35 - International Automatic Exchange of Information
Page 36 - Taxation of Distributions
Page 37 - Sale or Other Disposition of Common Shares
Page 38 - Information Reporting and Backup Withholding
Page 39 - Disclaimers About Non-U.S. Jurisdictions
Page 40 - N/A
Page 41 - N/A
Page 42 - N/A
Page 43 - N/A
Page 44 - N/A
Page 45 - TABLE OF CONTENTS
Page 46 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 47 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 48 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 49 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 50 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 51 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 52 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 53 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 54 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 55 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 56 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 57 - STATUTORY FINANCIAL STATEMENTS AC IMMUNE SA
Page 58 - Investing in our securities involves risks. See Risk Factors beginning on page 4 of this prospectus.
Page 59 - N/A
Page 60 - Neither the delivery of this prospectus nor any sale made under it implies that there has been no ch
Page 61 - N/A
Page 62 - N/A
Page 63 - N/A
Page 64 - N/A
Page 65 - N/A
Page 66 - N/A
Page 67 - N/A
Page 68 - N/A
Page 69 - N/A
Page 70 - N/A
Page 71 - N/A
Page 72 - N/A
Page 73 - N/A
Page 74 - N/A
Page 75 - N/A
Page 76 - N/A
Page 77 - N/A
Page 78 - N/A
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Page 82 - N/A
Page 83 - N/A
Page 84 - N/A
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - Subscription Rights